Prevalence of HPV-DNA and anti-HPV antibodies in women from girardot, Colombia

Sexually Transmitted Diseases

Volumn 36, Issue 5, 2009, Pages 290-296

  Leon, Sandra ^a   Sánchez, Ricardo ^a,b   Patarroyo, Manuel A ^a,b   Camargo, Milena ^a   Mejia, Adriano ^c   Urquiza, Mauricio ^b   Patarroyo, Manuel E ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c Hospital San Rafael de Girardot   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; VIRUS ANTIBODY; VIRUS DNA; CAPSID PROTEIN; EPITOPE; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIRTH; BLOOD SAMPLING; COLOMBIA; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREVALENCE; QUESTIONNAIRE; SEROLOGY; SEXUAL BEHAVIOR; SMOKING HABIT; SOCIAL STATUS; SQUAMOUS CELL; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS; AMINO ACID SEQUENCE; BLOOD; COMPARATIVE STUDY; EPIDEMIOLOGY; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; MOLECULAR GENETICS; RURAL POPULATION; SOCIOECONOMICS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIRION; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLOMBIA; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MASS SCREENING; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PEPTIDES; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; SOCIOECONOMIC FACTORS; UTERINE CERVICAL NEOPLASMS; VIRION;

EID: 67649994647     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318195762c     Document Type: Article

References (44)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
2. Lewis M. Análisis de la situation del cáncer cérvico-uterino en America Latina y el Caribe. Wahington, DC: OPS, 2004.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
5. Rajeevan MS, Swan DC, Nisenbaum R, et al. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 2005; 115:114-120.
6. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23:213-227.
7. Ho CM, Chien TY, Huang SH, et al. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006; 102:54-60.
8. Sun CA, Liu JF, Wu DM, et al. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002; 76:41-47.
9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
10. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(suppl 1):S16-S24.
11. Kahn JA, Lan D, Kahn RS. Socio-demographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 2007; 110:87-95.
12. Karem KL, Poon AC, Bierl C, et al. Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2002; 9:577-582.
13. Combita AL, Bravo MM, Touze A, et al. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58, and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002; 97:796-803.
14. Nonnenmacher B, Hubbert NL, Kimbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995; 172:19-24.
15. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997; 89:630-638.
16. Einstein MH, Studentsov YY, Ho GY, et al. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. Int J Cancer 2007; 120:55-59.
17. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-1919.
18. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13: 110-116.
19. Cason J, Kambo PK, Best JM, et al. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children. Int J Cancer 1992; 50:349-355.
20. Rocha-Zavaleta L, Ambrosio JP, Mora-Garcia Mde L, et al. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J Gen Virol 2004; 85:2643-2650.
21. Urquiza M, Guevara T, Espejo F, et al. Two L1-peptides are excellent tools for serological detection of HPV-associated cervical carcinoma lesions. Biochem Biophys Res Commun 2005; 332:224-232.
22. Urquiza M, Guevara T, Sanchez R, et al. A non-variable L1-peptide displays high sensitivity and specificity for detecting women having human papillomavirus-associated cervical lesions. Peptides 2008.
23. Urquiza M, Sanchez R, Amaya J, et al. L1-peptides were more specific than VLPs for detecting HPV-infected females having cervical lesions, attending Engativa Hospital, Colombia. J Clin Microbiol 2008.
24. Apgar BS, Zoschnick L, Wright TC Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003; 68:1992-1998.
25. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91:942-953.
26. Pagliusi SR, Garland SM. International standard reagents for HPV detection. Dis Markers 2007; 23:283-296.
27. Cervantes J, Lema C, Hurtado L, et al. Prevalence of human papillomavirus infection in rural villages of the Bolivian Amazon. Rev Inst Med Trop Sao Paulo 2003; 45:131-135.
28. Seedorf KOT, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 1987; 6:139-144.
29. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA. 1985; 82:5131-5135.
30. Touze A EMS, Sizaret PY, Mougin C, Munoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998; 36:2046-2051.
31. Delacour H, Servonnet A, Perrot A, et al. [ROC (receiver operating characteristics) curve: principles and application in biology]. Ann Biol Clin (Paris) 2005; 63:145-154.
32. Nelson JH, Hawkins GA, Edlund K, et al. A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol 2000; 38:688-695.
33. Saiki RK, Gelfand DH, Stoffel S, et al. Rimer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239:487-491.
34. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230:1350-1354.
35. de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76(Pt 4): 1057-1062.
36. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996; 34:2095-2100.
37. Lee YM LS, Chiang H, Fung CP, Liu WT. Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect 2001; 34:87-91.
38. Aho J, Komegay JR, Healey S, et al. Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the detection of human papillomavirus DNA by consensus PCR. J Clin Virol 2004; 29:127-133.
39. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl Environ Microbiol 1997; 63:3741-3751.
40. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996; 23:504-510.
41. Molano M, Weiderpass E, Posso H, et al. Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia Sex Transm Infect 2003; 79:474-478.
42. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87:324-333.
43. Uribe C DL, Ortiz Ricardo, et al. Pap smear prevalence and that of pre-malignant and malignant cervical lesions amongst women living in the Carmen initiative demonstration area, Bucaramanga, Colombia. Rev Colomb Obstet Ginecol 2006; 57:10-18.
44. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579-1588.